...
abbv-img

AbbVie Inc, Common Stock

ABBV

NYQ

$172.32

+$1.18

(0.69%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$304.29B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
51.29
Volume info-icon
This is the total number of shares traded during the most recent trading day.
4.29M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
6.24M
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
3.54%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.62
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$132.11 L
$179.55 H
$172.32

About AbbVie Inc, Common Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameABBVSectorS&P500
1-Week Return2.13%-0.78%-1.28%
1-Month Return1.03%0.89%1.37%
3-Month Return4.5%6.29%12.01%
6-Month Return6.53%6.29%15.36%
1-Year Return30%12.68%23.24%
3-Year Return67.97%21.13%36.17%
5-Year Return213.59%74.73%101.78%
10-Year Return382.42%182.71%236.91%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue33.27B45.80B56.20B58.05B54.32B[{"date":"2019-12-31","value":57.3,"profit":true},{"date":"2020-12-31","value":78.9,"profit":true},{"date":"2021-12-31","value":96.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.56,"profit":true}]
Cost of Revenue7.44B15.39B17.45B17.41B8.78B[{"date":"2019-12-31","value":42.64,"profit":true},{"date":"2020-12-31","value":88.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":50.33,"profit":true}]
Gross Profit25.83B30.42B38.75B40.64B45.54B[{"date":"2019-12-31","value":56.72,"profit":true},{"date":"2020-12-31","value":66.79,"profit":true},{"date":"2021-12-31","value":85.1,"profit":true},{"date":"2022-12-31","value":89.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin77.64%66.41%68.96%70.00%83.84%[{"date":"2019-12-31","value":92.61,"profit":true},{"date":"2020-12-31","value":79.21,"profit":true},{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":83.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses12.46B17.86B19.86B21.83B28.11B[{"date":"2019-12-31","value":44.32,"profit":true},{"date":"2020-12-31","value":63.52,"profit":true},{"date":"2021-12-31","value":70.66,"profit":true},{"date":"2022-12-31","value":77.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income12.98B476.00M17.92B18.12B17.43B[{"date":"2019-12-31","value":71.66,"profit":true},{"date":"2020-12-31","value":2.63,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.18,"profit":true}]
Total Non-Operating Income/Expense(6.07B)642.00M(5.90B)(5.34B)(12.86B)[{"date":"2019-12-31","value":-944.86,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-918.54,"profit":false},{"date":"2022-12-31","value":-831.31,"profit":false},{"date":"2023-12-31","value":-2002.96,"profit":false}]
Pre-Tax Income8.43B3.40B12.99B13.48B6.25B[{"date":"2019-12-31","value":62.52,"profit":true},{"date":"2020-12-31","value":25.21,"profit":true},{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true}]
Income Taxes544.00M(1.22B)1.44B1.63B1.38B[{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":-75,"profit":false},{"date":"2021-12-31","value":88.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.38,"profit":true}]
Income After Taxes7.88B4.62B11.55B11.85B4.87B[{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}]
Income From Continuous Operations7.88B4.62B11.55B11.85B4.87B[{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income7.88B4.62B11.54B11.84B4.86B[{"date":"2019-12-31","value":66.59,"profit":true},{"date":"2020-12-31","value":39,"profit":true},{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true}]
EPS (Diluted)8.9410.5112.6813.8711.11[{"date":"2019-12-31","value":64.46,"profit":true},{"date":"2020-12-31","value":75.78,"profit":true},{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ABBV
Cash Ratio 0.44
Current Ratio 0.94
Quick Ratio 0.83

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ABBV
ROA (LTM) 7.71%
ROE (LTM) 56.24%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ABBV
Debt Ratio Lower is generally better. Negative is bad. 0.95
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.05
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 18.59

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ABBV
Trailing PE 52.01
Forward PE 14.58
P/S (TTM) 5.29
P/B 27.74
Price/FCF 80
EV/R 6.15
EV/Ebitda 19.45
PEG NM

News

Ophthalmic Drugs Market Huge Growth in Future Scope 2024-2031 | Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG, Pfizer Inc.

Ophthalmic Drugs Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "Ophthalmic Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Ophthalmic Drugs market

18 Jul, 2024 a 10:31 am OpenPR

7 High-Yield Dividend Stocks to Help Pay Your Bills

While active acquisition is perhaps the most common methodology of gaining wealth, it’s not always the most efficient. For example, even if you trade your hours for a generous paycheck, there are only so many hours available: in a day, in a week, in a month, you get the idea. So, you need to find a way to have your money make money, which is where high-yield dividend stocks come into play. When participating in the equities space, it’s generally a good idea to have exposure to passive-income-providing enterprises. Your stable blue chips provide a frequent flow of income (typically on a quarterly basis). Space out your high-yield dividend stocks by their payment dates and you can potentially enjoy robust yields every month. This may allow you to pay your bills. Best of all, passive income is, well, passive. You don’t have to do anything to get the payout (so long as the company remains consistently profitable). With that in mind, below are high-yield dividend stocks to consider. PepsiCo (PEP) Source: FotograFFF / Shutterstock One of the world’s biggest beverage and snack product manufacturers, PepsiCo (NASDAQ: PEP ) makes a great case for high-yield dividend stocks.

17 Jul, 2024 a 6:18 pm InvestorPlace

Hidradenitis Suppurativa Market to Witness Huge Growth by 2031 - Pfizer Inc., Eli Lilly and Company, AbbVie Inc., UCB S.A., Incyte Corporation, Novartis AG.

DataM Intelligence has published a new research report on "Hidradenitis Suppurativa Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers.

17 Jul, 2024 a 9:11 am OpenPR

7 High-Yield Dividend Stocks Beating Inflation

At this writing, current inflation rate is 3% over the past 12 months. That’s the reading as of the end of June . So, in searching for high-yield dividend stocks beating inflation, I need to identify those with dividend yields above 3%. Fortunately, there are plenty of options in that range for investors. As always, it’s best to search within what is considered the healthy range of 2% to 6%. That’s a good rule of thumb, although there are exceptions to the rule. Consumers are fed up with inflation, although there are signs that it is continuing to abate. We are well above the target rate of 2%, driving investors and consumers to seek solutions. One solution is identifying and investing in stocks with dividends above the inflation rate. Doing so effectively cancels the negative effects of inflation to some degree. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE: ABBV ) is one of the better-known pharmaceutical stocks available to investors. It’s a stock well known to provide a strong dividend and is currently yielding 3.7%.

16 Jul, 2024 a 6:00 pm InvestorPlace

Trade Tracker: Rob Sechan sells Bristol Myers and buys more Abbvie

Rob Sechan, CEO of NewEdge Wealth, joins CNBC''s "Halftime Report" to discuss his latest moves. The Committee discuss the Healthcare sector.

16 Jul, 2024 a 5:08 pm CNBC

FAQs

What is AbbVie Inc share price today?

AbbVie Inc (ABBV) share price today is $172.32

Can Indians buy AbbVie Inc shares?

Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy AbbVie Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABBV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of AbbVie Inc be purchased?

Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.

How to invest in AbbVie Inc shares from India?

You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ABBV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in AbbVie Inc shares
What is AbbVie Inc 52-week high and low stock price?

The 52-week high price of AbbVie Inc (ABBV) is $179.55. The 52-week low price of AbbVie Inc (ABBV) is $132.11.

What is AbbVie Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 51.29

What is AbbVie Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 27.74

What is AbbVie Inc dividend yield?

The dividend yield of AbbVie Inc (ABBV) is 3.54%

What is the Market Cap of AbbVie Inc?

The market capitalization of AbbVie Inc (ABBV) is $304.29B

What is AbbVie Inc’s stock symbol?

The stock symbol (or ticker) of AbbVie Inc is ABBV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top